```html

Actinic Keratosis – A Complete Patient Guide

Overview

Actinic keratosis (AK), also called solar keratosis, is a rough, scaly lesion that develops on skin exposed to ultraviolet (UV) radiation over many years. AK is considered a precancerous condition because a small proportion can evolve into squamous cell carcinoma (SCC), the second most common skin cancer.

• Who it affects: Most commonly adults > 50 years, especially people with fair skin (Fitzpatrick skin types I‑II) who have a history of chronic sun exposure.
• Prevalence: In the United States, up to 34% of adults over 60 have at least one AK lesion; worldwide prevalence ranges from 2%‑10% in the general population, rising to > 50% in high‑sun‑exposure regions such as Australia and the Mediterranean coast (source: CDC, WHO, American Academy of Dermatology).
• Key point: Although most AKs are benign, they signal cumulative UV damage and warrant monitoring and treatment.

Symptoms

Actinic keratoses can be subtle and often go unnoticed. Below is a full list of characteristic findings:

• Texture: Rough, sandpaper‑like feel when touched.
• Color: Varies from skin‑colored, pink, red, brown, or yellow.
• Size: Typically 2‑10 mm; larger lesions may coalesce.
• Shape: Flat or slightly raised; sometimes with a central crust.
• Location: Most often on sun‑exposed areas – face (cheeks, nose, ears), scalp, neck, forearms, hands, and tops of the feet.
• Itching or tenderness: Mild pruritus or discomfort, especially after wind or heat exposure.
• Bleeding: Small amounts of blood if the lesion is scratched or traumatized.
• Change over time: Lesions may become thicker, develop a raised edge, or ulcerate – a red‑flag for possible malignant transformation.

Causes and Risk Factors

Primary cause

Chronic exposure to ultraviolet‑A (UVA) and UVB radiation damages DNA in skin cells, especially keratinocytes. Over time, this leads to abnormal cell growth and the formation of AK.

Key risk factors

• Skin type: Fair skin that burns easily, light hair, and blue or green eyes.
• Age: Cumulative sun exposure means risk increases after age 40, peaking in the 70s.
• Geography: Living at higher latitudes or at high altitude where UV intensity is greater.
• Outdoor occupation/hobbies: Farming, construction, sailing, skiing, golf.
• History of sunburns: Especially blistering burns before age 20.
• Immunosuppression: Organ‑transplant recipients, HIV infection, long‑term corticosteroid or biologic therapy.
• Previous skin cancer: History of basal cell carcinoma, squamous cell carcinoma, or melanoma increases the likelihood of AK.
• Genetics: Certain inherited DNA‑repair defects (e.g., xeroderma pigmentosum) dramatically raise risk.

Diagnosis

Diagnosis is primarily clinical but may involve adjunctive tools to confirm suspicious lesions.

Clinical examination

• Dermatologist inspects the skin, often using a handheld dermatoscope to view vascular patterns and surface texture.
• Typical dermoscopic features of AK include a “strawberry pattern” (white‑to‑yellow structureless areas with flaky scale) and reddish‑purple background.

Biopsy

If a lesion looks atypical or if there is concern for SCC, a shave, punch, or excisional biopsy is performed. Histopathology confirms dysplasia and rules out invasive cancer.

Additional tests (rare)

• Reflectance confocal microscopy (RCM): Non‑invasive imaging used in specialized centers.
• High‑resolution ultrasound: Helps assess lesion depth when surgical planning is needed.

Treatment Options

Therapy aims to eradicate existing lesions, reduce the total lesion count, and prevent malignant transformation. Choice depends on lesion number, size, location, patient health, and personal preference.

Topical medications

• 5‑Fluorouracil (5‑FU) cream 5%: Cytotoxic to dysplastic cells. Applied once or twice daily for 1–4 weeks; common side‑effects are redness, crusting, and pain.
• Imiquimod 5% cream: Immune response modifier that stimulates interferon‑α production. Used 2–3 times weekly for 6–12 weeks.
• Diclofenac 3% gel: A non‑steroidal anti‑inflammatory gel applied twice daily for 60–90 days; less irritation but slower response.
• Ingenol mebutate (Picato): Short‑course (2–3 days) field therapy for face/scalp or hands/arms; now less available in some countries due to safety concerns.

Procedural therapies

• Cryotherapy: Liquid nitrogen freeze; destroys lesion with minimal downtime. Ideal for isolated or few lesions.
• Curettage & Electrodessication (C&E): Scraping lesion followed by cauterization; useful for thick AKs.
• Photodynamic therapy (PDT): Application of a photosensitizing agent (ALA or MAL) followed by red light activation. Excellent for field cancerisation (multiple AKs on a contiguous area).
• Laser therapy: CO₂ or Er:YAG lasers vaporize superficial lesions; provides precise control but may require multiple sessions.
• Excision: Rare, reserved for lesions suspicious for SCC.

Lifestyle and supportive measures

• Broad‑spectrum sunscreen (SPF 30 or higher) applied daily.
• Protective clothing, wide‑brim hats, and UV‑blocking sunglasses.
• Regular skin self‑exams and annual dermatologist visits.

Living with Actinic Keratosis

While treatment can resolve existing lesions, the underlying sun‑damage remains, so ongoing management is essential.

Daily management tips

• Sun protection: Apply sunscreen 15 minutes before going outside; reapply every 2 hours, and after swimming or sweating.
• Self‑examination: Conduct a full‑body skin check once a month. Use a mirror for hard‑to‑see areas (back, scalp).
• Skin care routine: Use gentle, fragrance‑free cleansers; moisturize to maintain barrier function.
• Record keeping: Photograph lesions and keep a log of changes to discuss with your dermatologist.
• Healthy lifestyle: Balanced diet rich in antioxidants (vitamins C, E, beta‑carotene) may help skin repair; avoid tobacco and limit alcohol.

Psychosocial aspects

Visible lesions on the face or hands can affect self‑esteem. Consider support groups or counseling if you feel anxious about skin appearance or cancer risk.

Prevention

Because AK is a marker of cumulative UV injury, primary prevention targets sun exposure.

• Use sunscreen year‑round: Choose broad‑spectrum (UVA + UVB) with SPF 30‑50; apply ¼ teaspoon for the face and 1 ounce (a shot glass) for the entire body.
• Seek shade: Especially between 10 am–4 pm when UV intensity peaks.
• Wear protective clothing: UPF‑rated shirts, long sleeves, wide‑brim hats, and sunglasses with 100% UV protection.
• Avoid indoor tanning: Tanning beds emit UVA that dramatically increases AK risk.
• Regular dermatology visits: Early detection of AK and other skin cancers improves outcomes.

Complications

If left untreated, actinic keratosis can lead to several problems:

• Progression to squamous cell carcinoma (SCC): Estimated 0.1%‑5% of AKs become invasive SCC over 5 years; risk rises with lesion thickness, immunosuppression, and chronic field cancerisation.
• Field cancerisation: Multiple adjacent AKs create a zone of altered skin that may give rise to new lesions or SCC despite treatment of individual spots.
• Cosmetic concerns: Persistent scaly or pigmented lesions may be disfiguring, especially on the face.
• Secondary infection: Crusted or ulcerated AK can become infected, presenting with increased pain, swelling, or pus.

When to Seek Emergency Care

References

1. Mayo Clinic. Actinic keratosis. https://www.mayoclinic.org/…
2. American Academy of Dermatology. Actinic Keratosis: Diagnosis & Treatment. https://www.aad.org/…
3. Centers for Disease Control and Prevention (CDC). Skin Cancer Prevention. https://www.cdc.gov/…
4. World Health Organization. Ultraviolet (UV) Radiation and the Skin. https://www.who.int/…
5. Cleveland Clinic. Actinic keratosis treatment options. https://my.clevelandclinic.org/…
6. Robinson JK, et al. Management of Actinic Keratosis: A review of current recommendations. *J Am Acad Dermatol*. 2022;86(2):321‑334.

```